Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotaxel vs continuous 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer
2006-003086-14Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of larotaxel in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Sanofi. Primary endpoint: Overall survival. Started Aug 2006; status: completed.
02
Drugs
larotaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2006-003086-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003086-14.